

Patent Appln. No. 10/828,439
Atty. Docket No. PC19450D

IN THE CLAIMS

Claims 1-66 (canceled).

67. (new) A stabilized dry dosage form for reconstitution comprising:
dalbavancin; an effective stabilizer comprising a sugar; wherein the pH of the dosage
form is about 3 to about 5.

68. (new) The dosage form of claim 67, wherein the stabilizer comprises at least one
of mannitol, lactose, sucrose, sorbitol, glycerol, cellulose, trehalose, maltose, raffinose, or
dextrose.

69. (new) The dosage form of claim 67, which comprises about 100 mg to about
4000 mg dalbavancin.

70. (new) The dosage form of claim 67, wherein when reconstituted, the dalbavancin
has a ratio of multimer to monomer of at least 4.75:1.

71. (new) The dosage form of claim 67, wherein the stabilizer comprises mannitol.

72. (new) The dosage form of claim 71, wherein the weight ratio of stabilizer to
dalbavancin is about 1:2.

73. (new) The dosage form of claim 71, wherein the weight ratio of mannitol to
dalbavancin is about 1:2.

74. (new) The dosage form of claim 67, wherein the pH is about 3.5 to about 4.5.

75. (new) The dosage form of claim 67, wherein the pH is about 3.5.

76. (new) The dosage form of claim 67, wherein the pH is about 4.5.

77. (new) The dosage form of claim 67, which is lyophilized.

78. (new) The dosage form of claim 67, wherein the stabilizer comprises lactose.

Patent Appln. No. 10/828,439
Atty. Docket No. PC19450D

79. (new) The dosage form of claim 67, wherein the stabilizer comprises mannitol and lactose.

80. (new) The dosage form of claim 79, wherein the weight ratio of mannitol to lactose to dalbavancin is about 1:1:4.

81. (new) The dosage form of claim 80, wherein the pH is about 4.5.